Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 531 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Mellitus in Pregnancy Clear all
Active, not recruiting Phase 4 Interventional

Pentoxifylline in Diabetic Kidney Disease

NCT03625648
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

NCT02545049
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
173
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated Phase 2 Interventional

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

NCT04387448
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Barriers to Adherence to Recommended Follow-up in Women With a History of Gestational Diabetes

NCT01681147
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
2 online nutrition and exercise education classes, Self monitoring of blood glucose levels
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jul 21, 2026, 7:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional

Balance After Baby Intervention for Women With Recent Gestational Diabetes

NCT02744300
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
BABI-2 Lifestyle Intervention
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

NCT00660309
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Aliskiren, Irbesartan, Captopril
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Jul 21, 2026, 7:28 PM EDT
Not listed Not applicable Interventional

Continuous Glucose Monitoring for Personal Protective Equipment Evaluation

NCT05478070
View directory record Official record
Conditions
Diabetes Mellitus (DM)
Interventions
Dexcom G6
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jul 21, 2026, 7:28 PM EDT
Not listed No phase listed Observational

Ultrasound Findings in Diabetic Pregnancies

NCT06407388
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Patients Engaged in Prevention: Enhancing Outreach to Increase Patient Engagement in Diabetes Prevention

NCT03550066
View directory record Official record
Conditions
Preventive Health Services, Health Communication
Interventions
Values affirmation, No affirmation
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 2 Interventional

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

NCT00664027
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
RTA 402 (Bardoxolone Methyl)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional

Role of Macronutrient Diet Composition and Infant Metabolic Outcomes in Gestational Diabetes

NCT01719029
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Low-Carbohydrate/Higher Fat Diet, High Carbohydrate/Low fat diet
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 2 Interventional

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

NCT02552277
View directory record Official record
Conditions
Diabetic Nephropathies, Peripheral Nervous System Diseases
Interventions
PDA-002, Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Garden Grove, California • Orange, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

NCT04616027
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Impairment, Healthy
Interventions
PF-06882961 20 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jul 21, 2026, 7:28 PM EDT
Completed No phase listed Observational

Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium

NCT00559767
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
2,860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional

Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes

NCT03015480
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes Mellitus, Albuminuria
Interventions
Remote counseling
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Jul 21, 2026, 7:28 PM EDT
Recruiting Phase 4 Interventional

Empagliflozin Treatment in Kidney Transplant Recipients

NCT06013865
View directory record Official record
Conditions
Kidney Transplant, Chronic Kidney Disease
Interventions
Empagliflozin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Pragmatic Randomized Clinical Trial to Limit Weight Gain in Pregnancy and Prevent Obesity

NCT04724330
View directory record Official record
Conditions
Pregnancy Weight Gain, Postpartum Weight Retention, Childhood Obesity, Gestational Diabetes, Overweight and Obesity
Interventions
Healthy for Two/Healthy for You
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study of Adults With Autism Spectrum Disorders

NCT01093768
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin, Vasopressin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional

Frequency of Blood Glucose Monitoring in Patients With Gestational Diabetes

NCT01818557
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Blood glucose testing
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Danville, Pennsylvania • Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

NCT03804879
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Nidufexor, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jul 21, 2026, 7:28 PM EDT
Active, not recruiting Phase 2 Interventional

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated Phase 1 Interventional

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

NCT03840343
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
Interventions
Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 21, 2026, 7:28 PM EDT